politics

Trump's 100% Tariff on Generic Drugs Concerns Indian Manufacturers

23 Temmuz 2026Japan Times

president has announced a significant policy change that affects non-patented drug manufacturers, particularly those in India. They will have a two-year window to relocate their production to the U.S.
or face a steep 100% import tariff, which is set to double after the first year. This move has raised concerns among Indian drugmakers about the potential impact on their operations and the broader implications for the global pharmaceutical market.
India is one of the largest producers of generic drugs, supplying a significant portion of the world's medications. market has been a crucial destination for these drugs, and the proposed tariffs could force many companies to reconsider their manufacturing strategies.
This decision by the U.S. administration could disrupt the established supply chains of generic drugs, which have been a cornerstone of affordable healthcare in many countries.

NewsAI özeti

This article reflects the views of the Japan Times and does not necessarily represent the views of the author or the newsroom.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.